Insulin resistance and antidiabetic drugs

Biochemical Pharmacology

Volumn 58, Issue 10, 1999, Pages 1511-1520

  Bailey, Clifford J ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Antidiabetic drugs; Diabetes mellitus; Insulin; Insulin resistance; Syndrome X

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; METFORMIN; UNCLASSIFIED DRUG;

ARTICLE; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYNDROME X;

ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERINSULINISM; HYPERLIPIDEMIAS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; OBESITY;

EID: 0032865376     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00191-4     Document Type: Article

References (39)

1. Cahill G.F. Physiology of insulin in man. Diabetes. 20:1971;785-799.
2. Cheatham B., Kahn C.R. Insulin action and the insulin signalling network. Endocr Rev. 16:1995;117-142.
3. Consensus Development Conference on insulin resistance. Diabetes Care. 21:1998;310-314.
4. Reaven G.M. Role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607.
5. DeFronzo R.A., Ferrannini E. Insulin resistance A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease . Diabetes Care. 14:1991;173-194.
6. DeFronzo R.A. The triumvirate β-cell, muscle, liver. A collusion responsible for NIDDM . Diabetes. 37:1988;667-687.
7. Kelley D., Mitrakon A., Marsh H. Skeletal muscle glycolysis, oxidation and storage of an oral glucose load. J Clin Invest. 81:1988;1563-1571.
8. 13C nuclear magnetic resonance spectroscopy. N Engl J Med. 322:1990;223-228.
9. Olefsky J.M. Insulin resistance and insulin action An in vitro and in vivo perspective . Diabetes. 30:1981;148-162.
10. Groop L.C., Bonadonna R.C., DelPrato S., Ratheiser K., Zyck K., Ferrannini E., DeFronzo R.A. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest. 84:1989;205-213.
11. Jeng C.Y., Shen W.H., Fuh M.M., Chen Y.D., Reaven G.M. Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM. Diabetes. 43:1994;1440-1444.
12. Polonsky K.S., Sturis J., Bell G.I. Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med. 334:1996;777-783.
13. Reaven G.M., Chen Y.D., Hollenback C.B. Plasma insulin, C-peptide and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. J Clin Endocrinol Metab. 76:1995;44-48.
14. Reaven G.M. Pathophysiology of insulin resistance in human disease. Physiol Rev. 75:1995;473-486.
15. Kopelman P.G., Albon L. Obesity, non-insulin-dependent diabetes mellitus and the metabolic syndrome. Br Med Bull. 53:1997;322-340.
16. Kahn CR, Insulin receptors and insulin signaling in normal and disease states. In: International Textbook of Diabetes (Eds. Alberti KGMM, Zimmet P, DeFronzo RA and Keen H), 2nd Edn, pp. 437-467. John Wiley & Sons, Limited, Chichester, 1997.
17. Jokl R., Colwell J.A. Arterial thrombosis and atherosclerosis in diabetes. Diabetes Rev. 5:1997;316-330.
18. MacNalty AS (Ed.), The British Medical Dictionary, p. 1389. Caxton Publishing, London, 1961.
19. Kahn C.R. Insulin action, diabetogenesis, and the cause of type II diabetes. Diabetes. 43:1994;1064-1084.
20. White MF, The insulin signalling system and the IRS proteins. Diabetologia 40: S2-S17, 1997.
21. Lawrence J.C., Roach P.J. New insights into the role and mechanism of glycogen synthase activation by insulin. Diabetes. 46:1997;541-547.
22. Holman G.D., Kasuga M. From receptor to transporter Insulin signalling to glucose transport . Diabetologia. 40:1997;991-1003.
23. Yki-Jarvinen H. Glucose toxicity. Endocr Rev. 13:1992;415-431.
24. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 46:1997;3-10.
25. Marshall S., Garvey W.T., Traxinger R.R. New insights into the metabolic regulation of insulin action and insulin resistance Role of glucose and amino acids . FASEB J. 5:1991;3031-3036.
26. Feener E.P., King G.L. Vascular dysfunction in diabetes mellitus. Lancet. 350:(Suppl 1):1997;9-13.
27. Utriainen T., Takala T., Luotolahti M., Ronnemaa T., Laine H., Ruotsalainen U., Haaparanta M., Nuutila P., Yki-Jarvinen H. Insulin resistance characterizes glucose uptake in skeletal muscle but not in the heart in NIDDM. Diabetologia. 41:1998;555-559.
28. Skyler J.S. Glucose control in type 2 diabetes mellitus. Ann Int Med. 127:1997;837-839.
29. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853.
30. Bailey C.J. Diabetes control Treating a moving target . Intern Med. 17:1996;90-101.
31. Lebovitz H.E. Alpha-glucosidase inhibitors. Endocrinol Metab Clin North Am. 26:1997;539-551.
32. Groop L.C. Sulfonylureas in NIDDM. Diabetes Care. 15:1992;737-754.
33. Bailey C.J. New insulin secretagogues. Diabetes Rev Int. 7:1998;2-7.
34. Galloway J.A. Treatment of NIDDM with insulin agonists or substitutes. Diabetes Care. 13:1990;1209-1239.
35. Bailey C.J., Turner R.C. Metformin. N Engl J Med. 334:1996;574-579.
36. Stith B.J., Goalstone M.L., Espinoza R., Mossel C., Roberts D., Wiernsperger N. The antidiabetic drug metformin elevates receptor tyrosine kinase activity and inositol 1,4,5-trisphosphate mass in Xenopus oocytes. Endocrinology. 137:1996;2990-2999.
37. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 352:1998;854-865.
38. Kosmiski L., Eckel R.H. Anorectic agents in non-insulin dependent diabetes mellitus. Curr Opin Endocrinol Diabetes. 4:1997;36-39.
39. Day C., Bailey C.J. Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice. Int J Obes. 22:1998;619-623.